A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Brief Summary

Official Title: “A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma”

The purpose of this study is to evaluate the efficacy of ABT-888 in combination with temozolomide versus temozolomide alone in subjects with metastatic melanoma.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
  • Study Primary Completion Date: June 2014

Interventions Used in this Clinical Trial

  • Drug: temozolomide
    • 150 mg/m2 temozolomide daily for 5 days every 28 days
  • Drug: ABT-888
    • Either 20 mg or 40 mg BID for 7 days every 28 days
  • Drug: Placebo
    • Placebo BID for 7 days every 28 days

Arms, Groups and Cohorts in this Clinical Trial

  • Active Comparator: 1
    • TMZ + ABT-888 at 20 mg BID
  • Active Comparator: 2
    • TMZ + ABT-888 at 40 mg BID
  • Placebo Comparator: 3
    • TMZ + Placebo

Outcome Measures for this Clinical Trial

Primary Measures

  • Progression-Free Survival
    • Time Frame: Radiographic evaluation every 2 months, clinical evaluation monthly
      Safety Issue?: No

Secondary Measures

  • Overall Survival
    • Time Frame: Every 4 weeks or as needed after subject is registered as off-study, up to 18 months
      Safety Issue?: No
  • 12-month Survival Rate
    • Time Frame: Every cycle (28 days)
      Safety Issue?: No
  • 6-month Progression Free Survival Rate
    • Time Frame: Every cycle (28 days)
      Safety Issue?: No
  • Time to Disease Progression
    • Time Frame: Every cycle (28 days)
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Histologically (or cytologically) confirmed metastatic melanoma.
  • Unresectable Stage III or Stage IV metastatic melanoma.
  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
  • Subjects with no history of brain metastases demonstrated by a baseline MRI,or subjects with a history of previously treated brain metastases who have history of operable/SRS treatable brain metastases and completed surgical resection/stereotactic radiosurgery with or without adjuvant whole brain radiation at least 28 days prior to Day 1.
  • have baseline MRI that shows no evidence of active intercranial disease
  • have discontinued taking medications for symptom management of brain metastases at least 7 days prior to Day 1
  • 28 days since prior anti-cancer therapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.
  • Adequate hematologic, renal and hepatic function.
  • Partial Thromboplastin Time (PTT) is <= 1.5 x upper normal limit of institution's normal range and INR < 1.5.
  • Subject's with significant fluid retention may be allowed at the discretion of the PI.
  • Life expectancy > 12 weeks.
  • Females must not be pregnant.
  • Voluntarily signed informed consent.

Exclusion Criteria

  • Lactate Dehydrogenase (LDH) > 2 x Upper Limit of Normal (ULN).
  • Ocular malignant melanoma.
  • History of CNS metastases or leptomeningeal disease.
  • Prior treatment with Dacarbazine (DTIC) or Temozolomide (TMZ).
  • Prior DNA damaging agents or cytotoxic chemotherapy.
  • Prior Whole Brain Radiation Therapy.
  • Received an investigational agent within 28 days of study.
  • History of seizure disorder and/or taking medication for seizure disorder.
  • Active malignancy within the past 5 years, except cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.
  • Medical condition that would cause a high risk for toxicities.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • AbbVie (prior sponsor, Abbott)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Mark D McKee, MD, Study Director, AbbVie

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00804908